Transforming growth factor-beta (TGF-β) and brain tumours

被引：32

作者：

Luwor, Rodney B. ^{[1
]}

Kaye, Andrew H. ^{[1
,2
]}

Zhu, Hong-Han ^{[1
]}

机构：

[1] Univ Melbourne, Royal Melbourne Hosp, Dept Surg, Parkville, Vic 3050, Australia

[2] Univ Melbourne, Royal Melbourne Hosp, Dept Neurosurg, Parkville, Vic 3050, Australia

来源：

JOURNAL OF CLINICAL NEUROSCIENCE | 2008年 / 15卷 / 08期

关键词：

glioma; signalling; TGF-beta; therapy;

D O I：

10.1016/j.jocn.2008.01.003

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Since its discovery in the late 1970s considerable research has linked transforming growth factor-beta (TGF-beta) to several human diseases such as fibrosis, auto-immunity and cancer. TGF-beta acts initially as a growth inhibitory factor in early stages of tumour development. In contrast, as tumours evolve, they develop mechanisms to evade the growth-regulatory effects of TGF-beta, resulting in greater tumour invasiveness, increased metastatic potential and inhibition of surrounding immune responses. However, although extensively studied, the molecular mechanisms that trigger tumour cells to "switch" from TGF-beta-inhibited to TGF-beta-promoted are still not fully understood. Contradictory studies that demonstrate opposite cellular effects mediated by TGF-beta are abundant throughout the literature. This review summarizes the current molecular mechanisms involved in the tumour suppressive and tumour progressive characteristics of TGF-beta in brain tumours. Potential therapeutic agents that target TGF-beta and related proteins being evaluated against brain tumours is also discussed. (c) 2008 Elsevier Ltd. All rights reserved.

引用

页码：845 / 855

页数：11

共 110 条

[1] Induction of inhibitory Smad6 and Smad7 mRNA by TGF-β family members [J].

Afrakhte, M ;

Morén, A ;

Jossan, S ;

Itoh, S ;

Westermark, B ;

Heldin, CH ;

Heldin, NE ;

ten Dijke, P .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 249 (02) :505-511

[2]

Ashley DM, 1998, CANCER RES, V58, P302

[3]

Bertone S, 1999, EUR J IMMUNOL, V29, P23, DOI 10.1002/(SICI)1521-4141(199901)29:01<23::AID-IMMU23>3.0.CO

[4]

2-Y

[5] Transforming growth factor-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism [J].

Bhowmick, NA ;

Ghiassi, M ;

Bakin, A ;

Aakre, M ;

Lundquist, CA ;

Engel, ME ;

Arteaga, CL ;

Moses, HL .

MOLECULAR BIOLOGY OF THE CELL, 2001, 12 (01) :27-36

[6] TGFβ:: the molecular Jekyll and Hyde of cancer [J].

Bierie, Brian ;

Moses, Harold L. .

NATURE REVIEWS CANCER, 2006, 6 (07) :506-520

[7]

Bitzer M, 2000, GENE DEV, V14, P187

[8]

BODMER S, 1989, J IMMUNOL, V143, P3222

[9] High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene [J].

Bruna, Alejandra ;

Darken, Rachel S. ;

Rojo, Federico ;

Ocana, Alberto ;

Penuelas, Silvia ;

Arias, Alexandra ;

Paris, Raquel ;

Tortosa, Avelina ;

Mora, Jaume ;

Baselga, Jose ;

Seoane, Joan .

CANCER CELL, 2007, 11 (02) :147-160

[10] Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor [J].

Brunet, A ;

Bonni, A ;

Zigmond, MJ ;

Lin, MZ ;

Juo, P ;

Hu, LS ;

Anderson, MJ ;

Arden, KC ;

Blenis, J ;

Greenberg, ME .

CELL, 1999, 96 (06) :857-868

← 1 2 3 4 5 6 7 8 9 10 →